Keep regular sleep, movement, and supportive social contact in your week. Make time for activities you enjoy and use manageable routines when motivation is low.

Mood Support
A steadier mood can make everyday life feel more manageable, with enough emotional flexibility to respond to both enjoyable moments and ordinary challenges. Mood support focuses on that sense of balance, along with the calm, motivation, and resilience that help you stay engaged. Different people may need support with different parts of this experience. Emotional wellbeing is connected to normal brain signaling, nutritional status, recovery, and the demands placed on you. Essential nutrients provide a foundation for nervous-system function, while more targeted ingredients are used for specific mood or calming purposes. Their distinct roles help explain why choosing around a clear priority is useful. Patterns across everyday life give the routine context. You might follow how readily you settle after stress, maintain interest in familiar activities, or manage a demanding day. Looking at those experiences together helps you recognize meaningful changes and keep your approach focused on practical emotional wellbeing.
Warnings
- Check serotonin-related combinations: 5-HTP, tryptophan, SAMe, and St. John's wort can be unsuitable with antidepressants or other medicines affecting serotonin. Do not combine them without professional review of the full regimen.
- Mood conditions need coordinated care: People with bipolar disorder or marked changes in mood, sleep, or behavior should seek clinical advice before adding mood products. Some supplements can be unsuitable alongside psychiatric treatment.
- St. John's wort has major interactions: St. John's wort can reduce the effectiveness of several medicines, including some contraceptives, and can interact dangerously with others. Review it professionally rather than treating it as a harmless herbal alternative.
- Check medicine interactions: Ask a pharmacist or clinician to review your exact products alongside your medicines. The ingredient, amount, and treatment determine which combinations are suitable.
Goal guidance
Choose regular meals with varied protein foods, plants, and sources of unsaturated fat. Notice whether caffeine or alcohol affects your mood, anxiety, or sleep.
Adults seeking support for everyday emotional balance, stress resilience, and a more settled mood.
Review mood supplements with a clinician if you take psychiatric medicines or have bipolar disorder. Pregnancy and breastfeeding need individual advice, and supplement changes should be coordinated with prescribed treatment.
Notice patterns across days and weeks, including sleep, motivation, and how you manage normal demands. A consistent routine gives a clearer picture than judging a single good or difficult day.
Combining several mood-active ingredients can create unnecessary overlap. Start with a clear purpose, check compatibility, and keep supportive daily habits part of the routine.
Ingredients
The active form, L-methylfolate, can cross the blood-brain barrier to participate directly in neurotransmitter synthesis. It is often used as an adjunct therapy for mood disorders.
- Focuses on
- Most relevant for
- Individuals with low folate status or those seeking to nutritionally complement existing depression treatment under medical supervision.
Potential benefits
- Support for antidepressant response.High-dose L-methylfolate (15 mg) has shown efficacy in reducing symptoms when added to standard antidepressant therapy for individuals with an inadequate treatment response.
- Mood maintenance in deficiency.Maintaining adequate folate levels is associated with a lower risk of developing depressive symptoms, particularly in the elderly and those with identified nutritional deficiencies.
- Neurotransmitter synthesis support.Unconfirmed. As a critical cofactor in methylation, folate is theorized to support the synthesis of serotonin, dopamine, and norepinephrine, though direct mood improvement from this mechanism alone remains unproven in healthy populations.
Limitations
- Inconsistent form efficacy.While L-methylfolate shows clinical promise, evidence for standard synthetic folic acid in mood support is inconsistent and often yields no significant benefit in trials.
- No benefit for healthy adults.Supplementation has not demonstrated mood-enhancing effects in healthy individuals with already adequate dietary folate levels.
- Mixed perinatal evidence.Research on whether folate supplementation during pregnancy prevents postpartum or perinatal depression is contradictory, with multiple large cohort studies finding no significant association.
Things to consider
Consult a healthcare provider before use, especially if taking antidepressants or if you have an MTHFR genetic variant. Clinical benefits for resistant depression were specifically observed with the L-methylfolate form at 15 mg daily.
Study evidence
84 studiesLow folate status is associated with depression, and methylfolate may help some people whose depression has not responded adequately to antidepressants. Evidence for ordinary folic acid is inconsistent, and the available research does not establish a general mood benefit in healthy people.
Magnesium helps regulate the HPA axis (the body's central stress response system) and acts as a gatekeeper for NMDA receptors, preventing over-excitation of nerve cells. Bioavailable forms like glycinate or L-threonate are preferred for mental health benefits.
- Focuses on
- Most relevant for
- Adults seeking to support emotional resilience and mood stability through nutritional intake, especially those with low dietary magnesium.
Potential benefits
- Symptom Management.Unconfirmed. Some clinical trials suggest magnesium may help lower depressive symptom scores, but meta-analyses of placebo-controlled trials often show no significant benefit, making this effect unproven for the general population.
- Anxiety and Stress Support.Unconfirmed. Magnesium is suggested to help alleviate subjective anxiety and stress in vulnerable populations, though existing evidence is considered poor quality and requires further confirmation.
- Neurotransmitter Synthesis.As a vital cofactor in the production of brain chemicals like serotonin, magnesium is essential for maintaining the biological pathways that regulate mood and the nervous system.
Limitations
- Inconsistent Clinical Support.Major clinical guidelines and meta-analyses have found insufficient evidence to recommend magnesium for major depressive disorders, with several trials showing it performs no better than a placebo.
- Dependence on Deficiency Status.The relationship between magnesium and mood is often tied to deficiency; it is unclear if individuals with already adequate magnesium levels experience any additional mood benefits from supplementation.
- Causality Uncertainty.Much of the evidence is based on cross-sectional studies showing an association between low magnesium and mood difficulties, which does not prove that supplementation can prevent or treat these issues.
Things to consider
Long-term use of diuretics or proton pump inhibitors (PPIs) may deplete magnesium levels, which has been associated with an increased prevalence of depressive symptoms.
Study evidence
60 studiesMagnesium shows some promise for mood-related symptoms, but findings are mixed and a dependable benefit has not been established. Research in people with depression or other clinical difficulties does not necessarily extend to everyday mood in otherwise healthy adults.
Omega-3 fatty acids, particularly EPA and DHA, are integral components of brain cell membranes. EPA has demonstrated direct mood-stabilizing effects, likely by reducing inflammatory cytokines that can negatively impact brain function.
- Focuses on
- Most relevant for
- Adults with diagnosed depression, especially those currently receiving antidepressant treatment.
Potential benefits
- Symptom Reduction in MDD.Meta-analyses indicate that Omega-3 supplementation can significantly reduce the severity of symptoms in adults with a clinical diagnosis of major depressive disorder.
- Adjuvant Support.Omega-3 appears most effective when used alongside standard antidepressants, with some studies showing a higher rate of symptom remission compared to medication alone.
- High-EPA Formulation Efficacy.Research consistently suggests that preparations containing more than 50 percent EPA are more effective for mood support than DHA-predominant oils.
Limitations
- Ineffective for Prevention.Long-term clinical trials do not support the use of Omega-3 to prevent the onset of depression in the general population or healthy older adults.
- Limited General Mood Impact.Supplementation typically shows no benefit for mood scores or stress-induced emotional changes in individuals without a clinical diagnosis of depression.
- Mixed Specialized Evidence.Evidence remains inconclusive or null for preventing perinatal depression, treating bipolar mania, or improving mood in adolescents and children.
Things to consider
Common side effects include gastrointestinal upset and easy bruising. Some long-term studies in healthy older adults and men with cardiovascular disease observed a slight increase in depression risk.
Study evidence
141 studiesOmega-3 may reduce symptoms in adults with existing depression, with more favorable evidence for EPA-rich preparations used alongside antidepressants. It has not reliably improved mood in people without depression or prevented depression, and benefits vary across populations and studies.
Vitamin B12 is a necessary cofactor for the synthesis of SAMe, a molecule critical for producing serotonin, dopamine, and norepinephrine. The methylcobalamin form is biologically active and often recommended.
- Focuses on
- Most relevant for
- Individuals with low vitamin B12 levels or those at high risk of deficiency who are experiencing mood-related concerns.
Potential benefits
- Correction of deficiency-related symptoms.Addressing low vitamin B12 levels is critical for mood, as deficiency is consistently linked to increased depressive symptoms and melancholic mood subtypes.
- Support for long-term mood stability.Prolonged B12 intake over months or years may help reduce the risk of depressive relapse and the onset of clinical symptoms in at-risk populations.
- Improved affect in older adults.Maintaining healthy B12 status is associated with higher positive affect and better psychological well-being in community-dwelling older adults.
Limitations
- Ineffective for adequate levels.Supplementation typically provides no mood benefit for individuals who already have sufficient vitamin B12 levels.
- Minimal short-term impact.Short-term use (days to weeks) has not been shown to reduce the severity of symptoms in major depressive disorder.
- Mixed population evidence.Large-scale studies in general healthy populations often find no significant association between B12 levels and anxiety or depression symptoms.
Things to consider
Common medications such as metformin and proton pump inhibitors (PPIs) can impair B12 absorption. Persistently elevated B12 levels above 1,000 pg/mL have been associated with increased health risks in some observational studies.
Study evidence
29 studiesLow vitamin B12 is associated with depressive symptoms in some populations, but this does not show that extra B12 improves mood when levels are adequate. Supplementation findings are inconsistent, with possible benefits in selected clinical groups rather than a reliable general mood effect.
Vitamin B6, in its active P-5-P form, is an essential cofactor for enzymes converting 5-HTP to serotonin and L-DOPA to dopamine. Its role in the methylation cycle alongside B12 and folate makes it foundational for emotional well-being.
- Focuses on
- Most relevant for
- Individuals with low vitamin B6 status or those experiencing existing depressive symptoms seeking to support emotional well-being through nutritional replenishment.
Potential benefits
- Correction of Deficiency-Related Distress.Normalizing vitamin B6 levels may help reduce psychological distress and irritability, as low status is consistently associated with increased mood-related symptoms in observational studies.
- Depressive Symptom Reduction.High-dose supplementation has shown potential in reducing depressive symptoms in individuals already experiencing mild mood challenges, though it does not appear to provide the same benefit to those without existing symptoms.
- Targeted Situational Mood Support.Preliminary evidence suggests B6 may help lower the risk of postpartum depression in high-risk women and may mitigate mood-related side effects of specific medications.
Limitations
- Minimal General Anxiety Impact.Clinical trials focused on B6 specifically for mood have frequently found no significant reduction in anxiety or stress levels compared to a placebo.
- Inconsistent in Healthy Populations.Supplementation may not offer a mood-boosting advantage for healthy adults who already maintain adequate vitamin B6 levels through diet.
- Causal Uncertainty.While low B6 is linked to poorer mood, most evidence is cross-sectional; it remains unclear if low intake causes mood issues or if other factors are involved.
Things to consider
Long-term high-dose B6 intake should be supervised by a professional to avoid potential sensory nerve issues. This ingredient is most effective for mood when addressing an underlying deficiency rather than as a general performance enhancer.
Study evidence
19 studiesVitamin B6 shows preliminary promise for reducing depressive symptoms in selected groups, while low B6 status is associated with poorer mood. Supplement trials are inconsistent, and the evidence does not establish a general mood benefit for people whose B6 levels are already adequate.
Vitamin D receptors are abundant in areas of the brain associated with mood regulation. It helps control the synthesis of key neurotransmitters and protects neurons from oxidative damage.
- Focuses on
- Most relevant for
- Adults with clinical depressive symptoms, pregnant women, or older adults with low vitamin D status.
Potential benefits
- Symptom Severity Reduction.Meta-analyses of randomized trials indicate that supplementation may moderately reduce scores on standardized depression scales, particularly in individuals with mild to moderate clinical symptoms.
- Perinatal Mood Support.Daily intake of vitamin D3 during late pregnancy has been shown in clinical trials to effectively lower the risk and severity of depressive symptoms during the weeks following childbirth.
- Mental Health in Older Adults.Targeted supplementation may help alleviate symptoms of anxiety and depression in elderly populations, including those with concurrent health challenges such as prediabetes.
Limitations
- Inconsistent Clinical Evidence.Numerous placebo-controlled trials show no significant mood improvement in healthy adults or individuals who are not clinically depressed, regardless of their vitamin D blood levels.
- Questionable Causal Link.While low levels are strongly associated with poor mood, correcting a deficiency does not consistently result in emotional improvement, suggesting low vitamin D may be a marker rather than a cause.
- Not a Standalone Treatment.Research primarily evaluates vitamin D as an adjunct to standard care; it is not established as a primary replacement for standard antidepressant therapies or psychological counseling.
Things to consider
Supplementation appears most effective when targeted at populations with confirmed deficiency or significant depressive symptoms; benefits for general mood in healthy, replete individuals are not supported.
Study evidence
163 studiesVitamin D may modestly reduce depressive symptoms in some people, but supplementation results are inconsistent. Low vitamin D levels often accompany poorer mood, yet this association does not prove causation, and even correcting low levels does not reliably improve mood.
Studies
Explore published research for this goal.
Sources
Up to five highest-ranked published examples per ingredient. Study counts and charts include all published studies for the connection.
- The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials.
- Continuous supplementation of folic acid in pregnancy and the risk of perinatal depression-A meta-analysis.
- Efficacy of B-vitamins and vitamin D therapy in improving depressive and anxiety disorders: a systematic review of randomized controlled trials.
- Folate supplementation as a beneficial add-on treatment in relieving depressive symptoms: A meta-analysis of meta-analyses.
- Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study.
- Protective role of antioxidant supplementation for depression and anxiety: A meta-analysis of randomized clinical trials.
- Role of magnesium supplementation in the treatment of depression: A randomized clinical trial.
- Magnesium supplementation as an adjunct to fluoxetine therapy for depression.
- The effects of magnesium supplementation on serum level of brain derived neurotrophic factor (BDNF) and depression status in patients with depression.
- Dietary magnesium intake and risk of depression.
- Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial.
- Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials.
- Omega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study.
- Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.
- Omega-3 fatty-acids modulate symptoms of depressive disorder, serum levels of omega-3 fatty acids and omega-6/omega-3 ratio in children. A randomized, double-blind and controlled trial.
- Subjective well-being in older adults: folate and vitamin B12 independently predict positive affect.
- Association between of vitamin B12 status during pregnancy and probable postpartum depression: the ECLIPSES study.
- The biological relationship among depression, vitamins B9, B12, and D, and genetic variants: a systematic review.
- Associations of dietary B vitamins intakes with depression in adults.
- High Dose Vitamin B6 Reduces Depression Symptoms.
- Can Vitamin B6 Help to Prevent Postpartum Depression? A Randomized Controlled Trial.
- Associations of Dietary Intake of Vitamin B6 and Plasma Pyridoxal 5'-Phosphate Level With Depression in US Adults: Findings From NHANES 2005-2010.
- Impact of vitamin B6 status on psychological distress in a longitudinal study of HIV-1 infection.
- Meta-analysis of the effect of vitamin D on depression.
- A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers.
- Prospective associations between vitamin D and depression in middle-aged adults: findings from the UK Biobank cohort.
- Association Between Low Vitamin D Levels and Depression: A Systematic Review and Meta-Analysis.
- Vitamin D Alleviates Anxiety and Depression in Elderly People with Prediabetes: A Randomized Controlled Study.
- Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode.
- The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial.
- Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis.
- Tryptophan and 5-hydroxytryptophan for depression.
- 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study.
- A proprietary herbal extract of ashwagandha root for stress and anxiety in healthy adults: a randomized, double-blind, three-arm, placebo-controlled efficacy and safety study.
- Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis.
- A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults.
- Effects of multi-herb and ashwagandha root formulas on stress modulation: a randomized, double-blind, placebo-controlled clinical study.
- Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis.
- A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
- Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder.
- Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area.
- Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
- Dietary creatine intake and depression risk among U.S. adults.
- Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.
- The Effect of Acute Rhodiola rosea Ingestion on Exercise Heart Rate, Substrate Utilisation, Mood State, and Perceptions of Exertion, Arousal, and Pleasure/Displeasure in Active Men.
- Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence.
- Medicinal Plants in the Treatment of Depression. II: Evidence from Clinical Trials.
- Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
- Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
- S-adenosylmethionine blood levels in major depression: changes with drug treatment.
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
- The Effects of a Bacopa monnieri Extract (Bacumen®) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Effects of Bacopa monnieri (CDRI 08®) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial.
- The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects.
- Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial.
- Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults.
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
- GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
- A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
- A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.
- St John's wort for major depression.
- Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.
- A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review.
- Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial.
- Complementary therapies for clinical depression: an overview of systematic reviews.
- A systematic review of the effect of L-tryptophan supplementation on mood and emotional functioning
- Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer's Disease
- Clinical Use of Curcumin in Depression: A Meta-Analysis.
- Effect of curcumin supplementation on symptoms of anxiety: A systematic review and meta-analysis of randomized controlled trials.
- Efficacy of curcumin in depression: A grade-assessed systematic review and meta-analysis of randomized controlled trials.
- Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
- Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
- [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
- Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls.
- Erythrocyte glycine in depressed, hypomanic, and euthymic bipolar patients treated with lithium carbonate.
- The significant role of educational status in PKU patients: the beneficial effect of psychological support in depression.
- Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder.
- Therapy of depression by phenylalanine. Preliminary note.
- [DL-phenylalanine as an antidepressant. Open study (author's transl)].
- Do early-treated adults with phenylketonuria sense high phenylalanine levels?
- l-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
- L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.
- The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review.
- Comparison of the effects of two amino acids, Gamma-aminobutyric acid (GABA) and L-theanine, on sedation, anxiety, and cognition in preoperative surgical patients - A randomized controlled study.
- Anti-stress effect of theanine on students during pharmacy practice: positive correlation among salivary α-amylase activity, trait anxiety and subjective stress.
- Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study.
- Chemotypic diversity and neuroactive potential of Valeriana jatamansi Jones: a systematic review on phytochemistry, pharmacology and standardisation challenges.
- Valerian Root in Treating Sleep Problems and Associated Disorders-A Systematic Review and Meta-Analysis.
- Assessment of Valeriana officinalis l. (Valerian) for Conscious Sedation of Patients During the Extraction of Impacted Mandibular Third Molars: A Randomized, Split-Mouth, Double-Blind, Crossover Study.
- Effectiveness and safety of oral sedation in adult patients undergoing dental procedures: a systematic review.
- Zinc in depression: From development to treatment: A comparative/ dose response meta-analysis of observational studies and randomized controlled trials.
- Dietary zinc and iron intake and risk of depression: A meta-analysis.
- Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial.
- Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis.
- Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
- Oral intake of γ-aminobutyric acid affects mood and activities of central nervous system during stressed condition induced by mental tasks.
- Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression.
- The role of neurotransmitters in mediating the relationship between brain alterations and depressive symptoms in patients with inflammatory bowel disease.
- Occipital gamma-aminobutyric acid and glutamate-glutamine alterations in major depressive disorder: An mrs study and meta-analysis.
- Systematic review of gamma-aminobutyric-acid inhibitory deficits across the reproductive life cycle.